About Alpha-1 antitrypsin Drugs

Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.

Technavio’s analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of 35.42% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Baxter International
• CSL Behring
• Grifols
• Kamada

Other prominent vendors
• Abeona Therapeutics
• Alnylam Pharmaceuticals
• Applied Genetic Technologies
• Arrowhead Research
• Baxalta
• Biogen
• Chiesi
• Curaxys
• Laboratoire français du Fractionnement et des Biotechnologies
• ProBioGen
• ProMetic Life Sciences

Market driver
• Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
• For a full, detailed list, view our report

Market challenge
• Limited plasma fractionation capacity
• For a full, detailed list, view our report

Market trend
• Increasing awareness about therapy
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.